Department of Pediatrics, Wayne State University, Detroit, Michigan.
Department of Pediatrics, Women and Infants Hospital, Brown University, Providence, Rhode Island.
JAMA. 2014;312(24):2629-39. doi: 10.1001/jama.2014.16058.
Hypothermia at 33.5°C for 72 hours for neonatal hypoxic ischemic encephalopathy reduces death or disability to 44% to 55%; longer cooling and deeper cooling are neuroprotective in animal models.
To determine if longer duration cooling (120 hours), deeper cooling (32.0°C), or both are superior to cooling at 33.5°C for 72 hours in neonates who are full-term with moderate or severe hypoxic ischemic encephalopathy.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, 2 × 2 factorial design clinical trial performed in 18 US centers in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network between October 2010 and November 2013.
Neonates were assigned to 4 hypothermia groups; 33.5°C for 72 hours, 32.0°C for 72 hours, 33.5°C for 120 hours, and 32.0°C for 120 hours.
The primary outcome of death or disability at 18 to 22 months is ongoing. The independent data and safety monitoring committee paused the trial to evaluate safety (cardiac arrhythmia, persistent acidosis, major vessel thrombosis and bleeding, and death in the neonatal intensive care unit [NICU]) after the first 50 neonates were enrolled, then after every subsequent 25 neonates. The trial was closed for emerging safety profile and futility analysis after the eighth review with 364 neonates enrolled (of 726 planned). This report focuses on safety and NICU deaths by marginal comparisons of 72 hours' vs 120 hours' duration and 33.5°C depth vs 32.0°C depth (predefined secondary outcomes).
The NICU death rates were 7 of 95 neonates (7%) for the 33.5°C for 72 hours group, 13 of 90 neonates (14%) for the 32.0°C for 72 hours group, 15 of 96 neonates (16%) for the 33.5°C for 120 hours group, and 14 of 83 neonates (17%) for the 32.0°C for 120 hours group. The adjusted risk ratio (RR) for NICU deaths for the 120 hours group vs 72 hours group was 1.37 (95% CI, 0.92-2.04) and for the 32.0°C group vs 33.5°C group was 1.24 (95% CI, 0.69-2.25). Safety outcomes were similar between the 120 hours group vs 72 hours group and the 32.0°C group vs 33.5°C group, except major bleeding occurred among 1% in the 120 hours group vs 3% in the 72 hours group (RR, 0.25 [95% CI, 0.07-0.91]). Futility analysis determined that the probability of detecting a statistically significant benefit for longer cooling, deeper cooling, or both for NICU death was less than 2%.
Among neonates who were full-term with moderate or severe hypoxic ischemic encephalopathy, longer cooling, deeper cooling, or both compared with hypothermia at 33.5°C for 72 hours did not reduce NICU death. These results have implications for patient care and design of future trials.
clinicaltrials.gov Identifier: NCT01192776.
对于患有缺氧缺血性脑病的足月新生儿,在 33.5°C 下进行 72 小时的低温治疗可将死亡或残疾率降低到 44%至 55%;在动物模型中,更长时间的冷却和更深的冷却具有神经保护作用。
确定与 33.5°C 下 72 小时的冷却相比,更长时间(120 小时)、更深的冷却(32.0°C)或两者联合应用于中重度缺氧缺血性脑病的足月新生儿是否更优。
设计、地点和参与者:这是一项在美国国立卫生研究院儿童健康与人类发育研究所(NICHD)新生儿研究网络的 18 个中心进行的随机、2×2 析因设计临床试验,于 2010 年 10 月至 2013 年 11 月期间进行。
新生儿被分配到 4 个低温治疗组:33.5°C 下 72 小时、32.0°C 下 72 小时、33.5°C 下 120 小时和 32.0°C 下 120 小时。
主要结局为 18 至 22 个月时的死亡或残疾,目前正在进行中。在 50 名新生儿入组后,独立的数据和安全监测委员会为评估安全性(心律失常、持续性酸中毒、大血管血栓形成和出血、新生儿重症监护病房[NICU]内死亡)暂停了试验,随后每入组 25 名新生儿后再次评估。在第八次审查后,由于出现了新的安全性概况和无效性分析,有 364 名新生儿入组(计划入组 726 名)后,该试验被关闭。本报告重点关注安全性和 NICU 死亡率,通过 72 小时与 120 小时持续时间和 33.5°C 与 32.0°C 深度的边缘比较(预先定义的次要结局)。
NICU 死亡率为:33.5°C 下 72 小时组为 95 名新生儿中的 7 名(7%)、32.0°C 下 72 小时组为 90 名新生儿中的 13 名(14%)、33.5°C 下 120 小时组为 96 名新生儿中的 15 名(16%)和 32.0°C 下 120 小时组为 83 名新生儿中的 14 名(17%)。120 小时组与 72 小时组相比,NICU 死亡的调整风险比(RR)为 1.37(95%CI,0.92-2.04),32.0°C 组与 33.5°C 组相比,RR 为 1.24(95%CI,0.69-2.25)。120 小时组与 72 小时组和 32.0°C 组与 33.5°C 组之间的安全性结果相似,除了 120 小时组中有 1%发生严重出血,而 72 小时组中有 3%(RR,0.25[95%CI,0.07-0.91])。无效性分析确定,检测到更长时间冷却、更深冷却或两者联合应用于 NICU 死亡的统计学显著益处的可能性小于 2%。
对于患有中重度缺氧缺血性脑病的足月新生儿,与 33.5°C 下 72 小时的低温治疗相比,更长时间、更深的冷却或两者联合应用并未降低 NICU 死亡率。这些结果对患者护理和未来试验设计具有重要意义。
clinicaltrials.gov 标识符:NCT01192776。